source
- Novartis faces another setback while Novo drops Nordisk partnershipThe latest edition of Endpoints Weekly notes that Novartis experienced another failure, though the newsletter does not provide details about the product or trial. It also reports that Novo Nordisk…
- FDA approves Eli Lilly's oral SERD Inluriyo combo for second-line metastatic breast cancerThe FDA has given approval to a new combination therapy from Eli Lilly that includes its oral selective estrogen receptor degrader, Inluriyo, for patients with metastatic breast cancer who have pro…